



MINUTES

Utah Department of Health
Drug Utilization Review Board

Thursday, December 8th, 2016
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Jennifer Brinton, M.D., Board Chair
Sharon Weinstein, M.D.
Steve Lore, M.D.
Kim Michelson, D.D.S.
Katherine Smith, Pharm.D.

Keith Tolman, M.D.
Neal Catalano, Pharm.D.
Michael Symond, M.D.
Kumar Shah, M.Sc., P.Eng.
Holly Gurgle, Pharm.D.

Board Members Excused:

Aesha Drozdowski, Pharm.D.

Ben Berrett, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, Pharm D
Heather Santacruz, R.N.
Robyn Seely, Pharm D.
Megan Schlappi, C.Ph.T.

Susan Siegfried, M.D
Bryan Larson, Pharm.D.
Merelynn Berrett, R.N

Other Individuals Present:

Joanita Lake, U of U*
Joann LeFleur, U of U*
Valeria Gonzals, U of U*

Robert Nohavec, U of U Health Plans
Lori Howarth, Bayer
Cody Ball, Select Health

*UofU = University of Utah

Meeting conducted by: Jennifer Brinton, M.D.

1. **Welcome & Housekeeping:** Jennifer Brinton, M.D. opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of November Minutes:** Kumar Shah, M.Sc., P.Eng. made a motion to approve the minutes from November. Mike Symond, M.D. seconded the motion. Unanimous (10-0-0).
3. **Pharmacy and Therapeutics (P&T) Committee update:** Bryan Larson, Pharm.D., P&T Manager, updated the board on the P&T Committee. The P&T Committee met last month to discuss “Older Anticonvulsant Agents” and “Anti-Anxiety Benzodiazepines”. There will not be a P&T Committee meeting in December.

4. **Baclofen Quantity Limits:** Steve Lore, M.D. made a motion to remove the quantity limits on Baclofen. Neal Catalano, Pharm.D. seconded the motion. Unanimous (10-0-0).
5. **Insulin Pens and Vials:** Holly Gurgle, Pharm.D. made a motion to remove the Prior Authorization criteria on Insulin Pens. Kim Michelson, D.D.S. seconded the motion. Nine Board members voted in favor. One abstained (Neal Catalano, Pharm.D.). (9-0-1).
6. **New Board Member:** Jennifer Brinton, M.D. introduced Sharon Weinstein as a new physician on the board. She also informed the board that Susan Siegfried, M.D. would no longer be a voting board member as she had been hired by the Department of Health to be the Peer to Peer Educator for HB-437.
7. **Oral and Implantable Buprenorphine Products for the Treatment of Opiate Abuse (Probuphine, Bunavail, Suboxone, Zubsolv & generic):** Joanita Lake from the University of Utah Drug Regimen Review Center presented drug information including indications, studies, side effects, and other information about Oral and Implantable Buprenorphine Products for the Treatment of Opiate Abuse. Data was also presented about the utilization of the drugs in the Utah Medicaid population.
 - a. **Public Comment:** N/A
 - b. **Board Discussion:**
 1. Chad Hope, Pharm.D. explained Utah Medicaid's current Prior Authorization criteria on products for the treatment of opiate abuse and why this topic was brought back to the board.
 2. Kumar Shah, M.Sc., P.Eng. suggested implementing an educational program or a contract between the provider and the patient when one of these medications is started.
 3. Sharon Weinstein, M.D. questioned what data there was that showed that tapering and discontinuing buprenorphine products for the treatment of opiate abuse was effective for the patient.
 4. The board discussed in length the idea of requiring counseling or other mental health help for patients on these products.
 5. The board discussed what a written contract for management and withdrawal between the doctor and the patient would look like.
 6. The board discussed in length what the reauthorization criteria would look like and if there should be a time limit on how long a patient can be on these products.
 7. Keith Tolman, M.D. made a motion that the Utah Medicaid pharmacy policy team would rewrite the criteria to be more concise, and bring back options for the board to discuss at the next meeting. Sharon Weinstein, M.D. seconded the motion. Unanimous (10-0-0).
8. **Public Meeting Adjourned**
9. **The next meeting is scheduled for January 12th, 2017.**